BioAge Labs Inc. (BIOA Proposed) unveiled the terms for its IPO today – Wednesday, Sept. 18, 2024 – on the same day that the Federal Reserve cut interest rates by 50 basis points – the first U.S. interest-rate cut in four years. BioAge is offering 7.5 million shares at a price range of $17.00 to $19.00 to raise $135 million, if the IPO is priced at the $18.00 mid-point, according to its S-1/A filing dated Sept. 18, 2024. The IPO is expected to price next week – on Wednesday night, Sept. 25, to trade Thursday, Sept. 26, on the NASDAQ.
Goldman Sachs, Morgan Stanley, Jefferies and Citigroup are the joint book-runners.
BioAge is focused on developing treatments for obesity and other metabolic diseases, according to the prospectus.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on IPOScoop.com’s website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions or anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.